{"id":70030,"date":"2025-07-17T13:51:14","date_gmt":"2025-07-17T13:51:14","guid":{"rendered":"https:\/\/www.europesays.com\/us\/70030\/"},"modified":"2025-07-17T13:51:14","modified_gmt":"2025-07-17T13:51:14","slug":"antibody-discovery-market-size-to-surpass-usd-20-4-bn-by-2034-fueled-by-precision-medicine-and-biotech-innovation","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/70030\/","title":{"rendered":"Antibody Discovery Market Size to Surpass USD 20.4 Bn by 2034 Fueled by Precision Medicine and Biotech Innovation"},"content":{"rendered":"

<\/p>\n

According
\nto Statifacts, the global antibody discovery market size<\/b><\/a> is
\nprojected to surpass USD 20.43 billion by 2034, increasing from USD 8.95
\nbillion in 2025. The market is expanding at a solid CAGR of 9.54% from 2025 to
\n2034.<\/p>\n

In terms of revenue, the worldwide antibody
\ndiscovery market was calculated at USD 8.21 billion in 2024 and is anticipated
\nto reach around USD 15.44 billion by 2031. Growing demand for therapeutic
\nantibodies, increasing R&D expenditure in pharmaceutical and biotechnology
\ncompanies, and increasing adoption of antibody production in precision medicine
\nand undertakings in companion diagnostics are driving the growth of the market.<\/p>\n

<\/p>\n

This Report is Readily Available for
\nImmediate Delivery, Visit Here to Explore the Report Sample and In-depth
\nDatabook Now@ <\/b>https:\/\/www.statifacts.com\/stats\/databook-download\/7769<\/a> <\/p>\n

What is the Remarkable Potential of the
\nAntibody Discovery Market?<\/b><\/p>\n<\/p>\n

The antibody discovery market refers to the
\nsynthesis, distribution, and use of antibody discovery, which involves many
\ntechniques aimed at identifying and isolating antibodies with desired
\nproperties. Antibody discovery is a process aimed at identifying and generating
\nantibodies with a high degree of specificity for a particular target, often an
\nantigen. Antibodies are our immune system\u2019s way of protecting us from
\ninfections, allergens, and toxins. Rising demand for therapeutic antibodies,
\nincreasing research and development spending in biotechnology<\/b><\/a> and pharmaceutical
\ncompanies, and increasing adoption of antibody
\nproduction for in vitro diagnostics<\/b><\/a> and personalized
\nmedicine are driving the growth of the antibody discovery market.<\/p>\n

Benefits
\nof recombinant antibodies include fast production and high quality. An antibody
\nis a crucial protein component of the animal immune system that circulates in
\nthe blood, detects foreign bodies like bacteria and viruses, and neutralizes
\nthem. The key benefits of using monoclonal antibodies are that they have been
\nused to make drugs that have been more successful at treating specific
\ndiseases, like some cancers.<\/p>\n

\u2022 According to a report
\npublished in September 2022, the Umabs-DB shows that 162 antibody therapies
\nwere approved by at least one regulatory agency in the world, including 122
\napprovals in the US, followed by 114 in Europe, 82 in Japan, and 73 in China.
\nThe approved antibody therapies include 115 canonical antibodies, 14 antibody
\ndrug conjugates, seven bispecific antibodies, eight antibody fragments, three
\nradiolabeled antibodies, one antibody conjugate immunotoxin, two
\nimmunoconjugates, and 12 Fc-Fusion proteins.<\/p>\n

Quick Points: Antibody
\nDiscovery Market Insights<\/b><\/p>\n

\u2022 North
\nAmerica dominated the global landscape in 2024, capturing a commanding 37%
\nmarket share.<\/p>\n

\u2022 Asia-Pacific
\nis on track to become the fastest-growing region, with a projected CAGR of
\n11.76% from 2024 to 2034.<\/p>\n

\u2022 Phage
\ndisplay emerged as the leading method in 2023, contributing over 50% of total
\nrevenue.<\/p>\n

\u2022 Meanwhile,
\nthe hybridoma segment is poised for impressive growth, expected to expand at a
\nrobust CAGR of 12.14% during the forecast period.<\/p>\n

\u2022 The
\nchimeric antibody segment is set to be the fastest climber, projected to grow
\nat a striking CAGR of 12.52% over the forecast timeline.<\/p>\n

\u2022 In terms of
\nend-users, the pharmaceutical and biotechnology industry dominated in 2023,
\naccounting for over 41% of total revenues.<\/p>\n

\u2022 At the same
\ntime, research laboratories are expected to register the fastest growth, with a
\npredicted CAGR of 12.60% through 2034.<\/p>\n

Source: – <\/b>PubMed<\/b><\/a><\/p>\n


Antibody Discovery Launched by Prominent Players<\/b><\/p>\n\n\n

Sr. No.<\/b><\/p>\n<\/td>\n\n

Name of the Product<\/b><\/p>\n<\/td>\n\n

Name of the Brand<\/b><\/p>\n<\/td>\n\n

Product Specification<\/b><\/p>\n<\/td>\n<\/tr>\n\n\n

1.<\/p>\n<\/td>\n\n

New purification resin- \u2018Purolite AP+50\u2019<\/p>\n<\/td>\n\n

Ecolab Life Sciences<\/p>\n<\/td>\n\n

Purolite AP+50 supports cost-efficient, high-performance
\n bioprocessing at scale.<\/p>\n<\/td>\n<\/tr>\n\n\n

2.<\/p>\n<\/td>\n\n

Free antibody validation service<\/p>\n<\/td>\n\n

Boster Bio<\/p>\n<\/td>\n\n

Free antibody validation service giving scientists the power
\n to test antibodies under their exact experimental conditions before purchase.<\/p>\n<\/td>\n<\/tr>\n\n\n

3.<\/p>\n<\/td>\n\n

Development of Antibody and Antibody-Derived Proteins Program<\/p>\n<\/td>\n\n

European Commission<\/p>\n<\/td>\n\n

The development of an antibody and antibody-derived proteins
\n program for the prevention and treatment of infectious diseases with epidemic
\n potential.<\/p>\n<\/td>\n<\/tr>\n\n\n

4.<\/p>\n<\/td>\n\n

B-Body Express Antibody Expression Service<\/p>\n<\/td>\n\n

Invenra Inc.<\/p>\n<\/td>\n\n

This new offering allows biotechnology and pharmaceutical
\n companies to rapidly access Invenra\u2019s premier B-Body bispecific antibody
\n platform, delivering high-purity, validated bispecific antibodies derived
\n from partner-provided antibody sequences.<\/p>\n<\/td>\n<\/tr>\n

Source: –<\/b> The Hindu<\/b><\/a>, <\/b>OpenPR<\/b><\/a>, <\/b>Funds for NGOs<\/b><\/a>, <\/b>and <\/b>BusinessWire<\/b><\/a>
Antibody
\nDiscovery Market Major Trends<\/b><\/p>\n

How Does Technological Advancement Drive
\nthe Global Antibody Discovery Market?<\/b><\/p>\n

The major trends in the antibody discovery space are related to
\nincreasing interest in the applications of therapeutic antibodies and increased
\ninvestment by biotechnology and pharmaceutical<\/b><\/a> companies.<\/p>\n

\u2022 Growing demand for therapeutic antibodies:<\/b> Therapeutic
\nantibodies are highly used in the treatment of many diseases and disease
\nconditions, including infections, malignancies, autoimmune disorders, and
\ncardiovascular diseases. One key benefit of using monoclonal antibody therapy
\nis that they have been used to make drugs that have been more successful at
\ntreating specific diseases, like some cancers. The mechanism of action of
\ntherapeutic antibodies includes neutralization to block the pathophysiological
\nfunction of their target molecules. Therapeutic antibodies are high molecular
\nweight biopharmaceuticals<\/b><\/a> obtained by
\nculturing microorganisms and animal cells through genetic engineering. Due to
\nhigh specificity, target identification of the drug becomes clear, and higher
\nefficacy and fewer side effects can be expected.<\/p>\n<\/p>\n

\u2022 High research and development expenditure in pharmaceutical
\nand biotechnology companies:<\/b> R&D expenditure in pharmaceutical and
\nbiotechnology companies has a profound global impact. It advances global health
\nby developing treatments for a broad range of diseases and reduces the burden,
\nespecially in developing countries, by tackling infectious diseases.
\nBiotechnology research and development is the process of creating new products,
\ntechnologies, and therapies using biological processes to solve challenges in
\nhealthcare, agriculture, and environmental science. Research and development
\nare one of the biggest drivers of innovation in business. These can result in
\nthe development of new products and services, enhanced processes, and new ways
\nto interact with customers.<\/p>\n

Which potential factors impose significant concerns related to
\nthe antibody discovery markets growth?<\/b><\/p>\n

The
\nsignificant concerns related to growth in the antibody discovery sector relate
\nto the prohibitive costs of antibody production and increasing federal
\nregulations due to safety and disease transmission considerations.<\/p>\n

\u2022 High cost involved in the antibody production:<\/b>
\nAntibodies are expensive to produce. Most costs in monoclonal antibody
\nproduction include raw materials, labor, equipment, and facility expenses.
\nAccording to a report, the cost of antibody manufacturing generally exceeds $50
\nper gram of purified antibody or drug substance ($50\/g of DS), which is far
\nhigher than the target of $10\/g of DS required to make them affordable in some
\nof the world\u2019s poorest regions.<\/p>\n

Source: – <\/b>GCGH. Grand Challenges<\/b><\/a>\u00a0\u00a0<\/p>\n

\u2022 Stringent government regulations: <\/b>Stringent government
\nregulations divert resources away from core business activities and
\ntime-consuming and complex compliance processes. It may include limited
\nflexibility, interest rate risk, inflation risk, and lower returns. Government
\nreports may be biased or inaccurate, can be out of date, and non-specific to
\nthe business.<\/p>\n

Ready to Dive Deeper? Visit Here to Buy Databook and In-depth
\nReport Now! <\/b>https:\/\/www.statifacts.com\/order-databook\/7769<\/b><\/a> <\/b><\/p>\n

Antibody
\nDiscovery Market <\/b>Report
\nCoverage:<\/b><\/p>\n\n\n

Report
\n Attributes<\/b><\/p>\n<\/td>\n\n

Statistics<\/b><\/p>\n<\/td>\n<\/tr>\n\n\n

Market
\n Size in 2024<\/p>\n<\/td>\n\n

USD
\n 8.21 Billion<\/p>\n<\/td>\n<\/tr>\n\n\n

Market
\n Size in 2025<\/p>\n<\/td>\n\n

USD
\n 8.95 Billion<\/p>\n<\/td>\n<\/tr>\n\n\n

Market
\n Size in 2030<\/p>\n<\/td>\n\n

USD
\n 14.04 Billion<\/p>\n<\/td>\n<\/tr>\n\n\n

Market
\n Size in 2032\u00a0\u00a0\u00a0 <\/p>\n<\/td>\n\n

USD
\n 17 Billion<\/p>\n<\/td>\n<\/tr>\n\n\n

Market
\n Size by 2034<\/p>\n<\/td>\n\n

USD
\n 20.43 Billion<\/p>\n<\/td>\n<\/tr>\n\n\n

CAGR
\n 2025-2034<\/p>\n<\/td>\n\n

9.54%<\/p>\n<\/td>\n<\/tr>\n\n\n

Leading
\n Region in 2024<\/p>\n<\/td>\n\n

North
\n America<\/p>\n<\/td>\n<\/tr>\n\n\n

Fastest
\n Growing Region<\/p>\n<\/td>\n\n

Asia
\n Pacific<\/p>\n<\/td>\n<\/tr>\n\n\n

Base
\n Year<\/p>\n<\/td>\n\n

2024<\/p>\n<\/td>\n<\/tr>\n\n\n

Forecast
\n Years<\/p>\n<\/td>\n\n

2025-2034<\/p>\n<\/td>\n<\/tr>\n\n\n

Segments
\n Covered<\/p>\n<\/td>\n\n

Method,
\n Antibody Type, End-user, and Region<\/p>\n<\/td>\n<\/tr>\n\n\n

Region
\n Covered<\/p>\n<\/td>\n\n

North
\n America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)<\/p>\n<\/td>\n<\/tr>\n\n\n

Key
\n Players<\/p>\n<\/td>\n\n

Eurofins
\n Scientific, Evotec, Twist Bioscience, Genscript Technology Corporation, Biocytogen,
\n Sartorius AG, Danaher Corporation, Fairjourney Biologics S.A, Creative
\n Biolabs, Charles River Laboratories<\/p>\n<\/td>\n<\/tr>\n

How Big Is the Development of the Antibody Discovery Platforms?<\/b><\/p>\n

Antibody discovery platform allows specific, epitope-directed discovery for
\noptimal functionality, specificity, affinity, internalization, and
\ndevelopability. Antibody discovery offers benefits like high stability, solubility,
\nand tissue penetration, making them attractive for therapeutic applications.<\/p>\n

Antibody discovery platform addresses the challenges, including improving
\nbinding precision & affinity, and design strategies for specific targets.
\nAntibody discovery improves sensitivity in diagnostics like affimer proteins as
\nsynthetic antibodies, quantum plasmonic <\/p>\n

immunoassay<\/b><\/a> sensing,
\ndevelopment of therapeutic antibodies, advancements in lateral flow assays
\n(LFAs), and improved antigen-antibody interaction.<\/p>\n

\u00a0<\/p>\n

Source: – <\/b>Precision Antibody<\/b><\/a><\/p>\n


How Big Is the Success of the North American Antibody Discovery Market?<\/b><\/p>\n

North America dominated the global antibody discovery market share of 37% in
\n2024.<\/b> Rising applications of monoclonal antibodies, booming biologics market<\/b><\/a>, elevated
\nrate of approval and adoption in the U.S. & Europe, growing research and
\ndevelopment activities, as well as increasing use of these antibodies due to
\ntheir high specificity, allowing for precision therapies to combat several
\ndiseases. These factors are driving expansion in the in North American market.<\/p>\n

\u2022 In November 2024, the U.S. Food and Drug Administration (FDA)
\naccelerated approval of Ziihera 50mg\/mL for injection for intravenous use for
\nthe treatment of adults with previously treated unresectable or metastatic
\nHER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an
\nFDA-approved test, was announced by Jazz Pharmaceuticals, plc.<\/p>\n

Source: – <\/b>Jazz Pharmaceuticals<\/b><\/a><\/p>\n

\"A<\/b><\/p>\n

\u00a0<\/b><\/p>\n

How is the Opportunistic Rise of the Asia
\nPacific in the Antibody Discovery Market?<\/b><\/p>\n

Asia Pacific is anticipated to grow at the fastest rate in the market during
\nthe forecast period.<\/b> Growing demand for therapeutic antibodies, increasing
\nR&D in pharmaceutical and biotechnology companies, and increasing adoption of personalized
\nmedicine<\/b><\/a> and companion diagnostics are contributing to the expansion of
\nthe antibody discovery market in the Asia Pacific region.<\/p>\n


How Is the State of the Antibody Discovery Market in China, India, and Japan?<\/b><\/p>\n

\u2022 In October 2020, to develop SARS-CoV-2 neutralizing monoclonal
\nantibodies (mAbs) co-invented by the Scripps Research and International AIDS
\nVaccine Initiative as innovative interventions to address the COVID-19
\npandemic, International AIDS Vaccine Initiative, a non-profit research
\norganization aiming to address the urgent and unmet global health challenges
\naround the treatment of AIDS, and Serum Institute of India Pvt. Ltd, a major
\nmanufacturer of biologics including vacines, announced an agreement with Merck
\nKGaA, Darmstadt, Germany, a leading science and technology company.<\/p>\n

Source: – <\/b>iavi<\/b><\/a><\/p>\n

\u2022 In June 2025, the key technology of the independently
\ndeveloped RenMab fully human antibody mouse platform has been granted an
\ninnovation patent by the Japan Patent Office (JPO) was announced by Biocytogen
\nPharmaceuticals (Beijing) Co., Ltd. This milestone denotes a significant leap
\nin strengthening the global intellectual property portfolio of the RenMice
\nfully human antibody platform family.<\/p>\n

Source: – <\/b>BusinessWire<\/b><\/a><\/p>\n


Antibody Discovery Market Segmentation Analysis<\/b><\/p>\n


Methods Analysis<\/b><\/p>\n

Antibody Discovery Market Size by Methods, 2024 to 2034 (USD
\nBillion)<\/b><\/p>\n\n\n

Segments<\/b><\/p>\n<\/td>\n\n

2024<\/b><\/p>\n<\/td>\n\n

2025<\/b><\/p>\n<\/td>\n\n

2026<\/b><\/p>\n<\/td>\n\n

2034<\/b><\/p>\n<\/td>\n<\/tr>\n\n\n

Phage
\n Display<\/b><\/p>\n<\/td>\n\n

4.134<\/p>\n<\/td>\n\n

4.427<\/p>\n<\/td>\n\n

4.743<\/p>\n<\/td>\n\n

8.609<\/p>\n<\/td>\n<\/tr>\n\n\n

Hybridoma<\/b><\/p>\n<\/td>\n\n

2.477<\/p>\n<\/td>\n\n

2.762<\/p>\n<\/td>\n\n

3.082<\/p>\n<\/td>\n\n

7.674<\/p>\n<\/td>\n<\/tr>\n\n\n

Others<\/b><\/p>\n<\/td>\n\n

1.596<\/p>\n<\/td>\n\n

1.759<\/p>\n<\/td>\n\n

1.938<\/p>\n<\/td>\n\n

4.146<\/p>\n<\/td>\n<\/tr>\n

The phage display segment held a dominant presence in the
\nantibody discovery market in 2024.<\/b> One of the key benefits of phage display
\nis its unique characteristic to generate large libraries of diverse antibodies
\nrelatively quickly. This is due to the technique involves inserting genes
\nencoding antibody fragments into bacteriophages, which are then used to create
\na library of phages displaying many antibody fragments. Antibody phage display
\n(APD) allows in vitro selection of human mAbs of virtually any specificity and
\naffinity.<\/p>\n

The hybridoma segment is expected to grow at the fastest rate in the market
\nduring the forecast period of 2025 to 2034.<\/b> Hybridoma techniques produce
\nmonoclonal antibodies (mAb) by fusing a specific antibody-producing B-cell with
\na myeloma cell, creating a hybrid cell called a hybridoma. Hybridoma technology
\noffers unlimited quantities of consistent, cost-effective, and homogenized
\nantibody production. Hybridoma is perfect for research, assay development, and
\ndownstream research, diagnostic, and therapeutic uses.<\/p>\n

Antibody Type Analysis<\/b><\/p>\n

Antibody Discovery Market Size by Antibody Type, 2024 to 2034 (USD
\nBillion)<\/b><\/p>\n\n\n

Segments<\/b><\/p>\n<\/td>\n\n

2024<\/b><\/p>\n<\/td>\n\n

2025<\/b><\/p>\n<\/td>\n\n

2026<\/b><\/p>\n<\/td>\n\n

2034<\/b><\/p>\n<\/td>\n<\/tr>\n\n\n

Humanized
\n Antibody<\/p>\n<\/td>\n\n

3.320<\/p>\n<\/td>\n\n

3.561<\/p>\n<\/td>\n\n

3.822<\/p>\n<\/td>\n\n

7.020<\/p>\n<\/td>\n<\/tr>\n\n\n

Human Antibody<\/p>\n<\/td>\n\n

2.154<\/p>\n<\/td>\n\n

2.340<\/p>\n<\/td>\n\n

2.545<\/p>\n<\/td>\n\n

5.178<\/p>\n<\/td>\n<\/tr>\n\n\n

Chimeric
\n Antibody<\/p>\n<\/td>\n\n

1.770<\/p>\n<\/td>\n\n

1.979<\/p>\n<\/td>\n\n

2.214<\/p>\n<\/td>\n\n

5.669<\/p>\n<\/td>\n<\/tr>\n\n\n

Murine
\n Antibody<\/p>\n<\/td>\n\n

0.963<\/p>\n<\/td>\n\n

1.068<\/p>\n<\/td>\n\n

1.183<\/p>\n<\/td>\n\n

2.562<\/p>\n<\/td>\n<\/tr>\n

The human antibody segment accounted for a considerable share of
\nthe antibody discovery market in 2024.<\/b> Fully human monoclonal
\nantibodies (mAbs) are derived completely from human subjects. These antibodies
\nmimic the structure and function of naturally occurring human immune proteins,
\noffering significant benefits in precision, safety, and therapeutic efficacy.
\nThe human body has five different types of antibodies, including
\nimmunoglobulins like IgA, IgD, IgG, IgE, and IgM are different immunoglobulin
\nisotypes.<\/p>\n

The murine antibody segment is projected to experience the fastest rate of
\nmarket growth from 2025 to 2034.<\/b> Murine antibodies are made by the immune
\nsystem in response to substances that are foreign to the organism. Donor
\nsources like mice and rats are being used for the production of specific
\nantibodies. Murine antibodies are engineered to reduce their natural
\nimmunogenicity towards human patients.<\/p>\n

End-users Analysis<\/b><\/p>\n

Antibody Discovery Market Size by End-users, 2024 to 2034 (USD Billion)<\/b><\/p>\n\n\n

Segments<\/b><\/p>\n<\/td>\n\n

2024<\/b><\/p>\n<\/td>\n\n

2025<\/b><\/p>\n<\/td>\n\n

2026<\/b><\/p>\n<\/td>\n\n

2034<\/b><\/p>\n<\/td>\n<\/tr>\n\n\n

Pharmaceutical
\n and Biotechnology industry<\/p>\n<\/td>\n\n

3.362<\/p>\n<\/td>\n\n

3.563<\/p>\n<\/td>\n\n

3.780<\/p>\n<\/td>\n\n

6.352<\/p>\n<\/td>\n<\/tr>\n\n\n

Research
\n laboratory<\/p>\n<\/td>\n\n

2.841<\/p>\n<\/td>\n\n

3.181<\/p>\n<\/td>\n\n

3.565<\/p>\n<\/td>\n\n

9.158<\/p>\n<\/td>\n<\/tr>\n\n\n

Others<\/p>\n<\/td>\n\n

2.004<\/p>\n<\/td>\n\n

2.203<\/p>\n<\/td>\n\n

2.419<\/p>\n<\/td>\n\n

4.919<\/p>\n<\/td>\n<\/tr>\n

The pharmaceutical & biotechnology industry segment led the
\nantibody discovery market. Antibodies are used in biotechnology in tests to
\ndetect and monitor infectious agents like HIV, the cause of AIDS, or the
\ninfluenza virus causing pandemic flu, and for identifying diseases released by
\nbiological weapons like anthrax and smallpox.<\/p>\n<\/p>\n

The academic laboratory segment is set to experience the highest
\ngrowth rate of the market between 2025 to 2034. Antibodies are the immune
\nsystem\u2019s way of protecting us from infections, allergens, and toxins.
\nAntibodies are an increasingly indispensable component in several diagnostic
\nassays. Antibody uses include the detection of infections, the idenficiation of
\nallergens, and the measurement of hormones and other biological markers in
\nblood.<\/p>\n

See More Related Reports:<\/b><\/p>\n

\u2022 The U.S. antibody drug
\nconjugates market<\/b><\/a> size was estimated at USD 4,020 million in
\n2024 and is projected to be worth around USD 12,050 million by 2034, growing at
\na CAGR of 11.6% from 2024 to 2034.<\/p>\n<\/p>\n

\u2022 The global anti neurofilament L antibody market<\/b><\/a> size was valued at USD
\n323 million in 2024 and is predicted to gain around USD 807.81 million by 2034
\nwith a CAGR of 9.6%.<\/p>\n

\u2022 The U.S. biosimilar monoclonal
\nantibody market<\/b><\/a> size accounted for USD 3,210 million in 2024
\nand is expected to exceed around USD 26,500 million by 2034, growing at a CAGR
\nof 23.5% from 2025 to 2034.<\/p>\n

\u2022 The global eDiscovery market<\/b><\/a> size is
\ncalculated at USD 13,141 million in 2024 and is predicted to attain around USD
\n29,439 million by 2034, expanding at a CAGR of 8.4% from 2024 to 2034.<\/p>\n

\u2022 The global drug discovery market<\/b><\/a> size is
\ncalculated at USD 65.88 billion in 2024 and is predicted to reach around USD
\n160.31 billion by 2034, expanding at a CAGR of 9.3% from 2024 to 2034.<\/p>\n

\u2022 The global cloud-based drug discovery platform
\nmarket<\/b><\/a>
\nsize is predicted to gain around USD 8,029 million by 2034 from USD 2,429
\nmillion in 2024 with a CAGR of 12.7%.<\/p>\n

Competitive Landscape in the Antibody Discovery Market<\/b><\/p>\n

<\/p>\n

\u2022 Danaher Corporation:<\/b> Danaher is a leading innovator in
\nlife sciences and diagnostics worldwide, committed to harnessing the tools of
\nscience and technology to improve human health.<\/p>\n

\u2022 Eurofins Scientific:<\/b> Eurofins Scientific is a national
\nleader in laboratory services, serving food, environment, pharmaceutical, and
\nagroscience customers.<\/p>\n

\u2022 Evotec:<\/b> Evotec is a large drug discovery and
\ndevelopment company which often collaborates with other players in the space.
\nIt discovers and develops small-molecule drugs spanning various disease areas.<\/p>\n

\u2022 Twist Bioscience:<\/b> This is a biotechnology company that
\noffers synthetic DNA solutions, gene synthesis, and variant libraries.<\/p>\n

\u2022 Charles<\/b> River<\/b> Laboratories:<\/b> Charles River
\nLaboratories supplies essential products and services to assist many
\nhealthcare-related government agencies, pharmaceutical and biotechnology
\ncompanies, and leading academic institutions around the world in accelerating
\ntheir research undertakings and drug development efforts.<\/p>\n

\u2022 Genscript Technology Corporation:<\/b> Genscript Technology
\nCorporation accelerates innovation in biotechnology and healthcare by providing
\nresearchers and companies with the building blocks needed to develop
\ngroundbreaking treatments and products.<\/p>\n

\u2022 Biocytogen:<\/b> Biocytogen provides integrated solutions
\nfor next-generation antibody drug development to the global biomedical
\ncommunities.<\/p>\n

\u2022 Sartorius AG:<\/b> Sartorius AG is a Germany-based supplier
\nof pharmaceutical and laboratory equipment.<\/p>\n

\u2022 Fairjourney Biologics S.A.:<\/b> They specialize in
\ncustomized services and technologies for optimal antibody solutions.<\/p>\n

\u2022 Creative Biolabs:<\/b> They offer world-class, cutting-edge
\nrecombinant antibodies for biomedical research.<\/p>\n

What Is Going Around the Globe in the Antibody Discovery Market?<\/b><\/p>\n

\u2022 In June 2025, an innovative new resin to help achieve cost
\nsavings and improve operations throughout the antibody manufacturing process
\nwas launched by Ecolab Life Sciences.<\/p>\n

Source: – <\/b>Cleanroom Technology<\/b><\/a><\/b><\/p>\n

\u2022 In May 2025, the global IDeate-Esophageal01 Phase 3 trial of a
\nnew antibody drug conjugate in advanced esophageal squamous cell carcinoma was
\nlaunched by Merck and Daiichi Sankyo.<\/p>\n

Source: – <\/b>Applied Clinical Trials Online<\/b><\/a><\/p>\n


Antibody Discovery Market Segments Covered in the Report<\/b><\/p>\n


By Methods<\/b><\/p>\n

\u2022 Phage Display<\/p>\n

\u2022 Hybridoma<\/p>\n

\u2022 Others<\/p>\n

By Antibody Type<\/b><\/p>\n

\u2022 Humanized Antibody<\/p>\n

\u2022 Human Antibody<\/p>\n

\u2022 Chimeric Antibody<\/p>\n

\u2022 Murine Antibody<\/p>\n

By End Users<\/b><\/p>\n

\u2022 Pharmaceutical and Biotechnology industry<\/p>\n

\u2022 Research laboratory<\/p>\n

\u2022 Others<\/p>\n

By Geography<\/b><\/p>\n

\u2022 North America<\/p>\n

\u2022 Europe<\/p>\n

\u2022 Asia-Pacific<\/p>\n

\u2022 Latin America<\/p>\n

\u2022 Middle East and Africa<\/p>\n

Ready
\nto Dive Deeper? Visit Here to Buy Databook and In-depth Report Now! <\/b>https:\/\/www.statifacts.com\/stats\/databook-download\/7769<\/b><\/a><\/p>\n

\ud835\udc00\ud835\udc1b\ud835\udc28\ud835\udc2e\ud835\udc2d \ud835\udc14\ud835\udc2c:<\/p>\n

Statifacts is a global
\nmarket intelligence and consulting leader, committed to delivering deep
\nstrategic insights that fuel innovation and transformation. With a sharp focus
\non the fast-evolving landscape of life sciences, we excel at navigating the
\nintricacies of cell and gene therapies<\/b><\/a>, oncology<\/b><\/a>, and drug
\ndevelopment. We empower our clients, ranging from biotech pioneers to
\ninstitutional investors with the intelligence needed to lead in high-impact
\nareas like regenerative medicine, cancer therapeutics, and precision health.
\nOur broad expertise across the pharma-biotech value chain is backed by robust,
\nstatistically driven data for every market we cover, ensuring decisions are
\ninformed, forward-looking, and built for impact.<\/p>\n

Statifacts offers subscription services for data and analytics
\ninsights. This page provides options to explore and purchase a subscription tailored
\nto your needs, granting access to valuable statistical resources and tools.
\nAccess here – https:\/\/www.statifacts.com\/get-a-subscription<\/b><\/a><\/p>\n

Connect with Us<\/b><\/p>\n

Ballindamm 22, 20095 Hamburg, Germany<\/p>\n

Europe: +44 7383092044<\/b><\/p>\n

Web: <\/b>https:\/\/www.statifacts.com\/<\/b><\/a><\/p>\n

For Latest Update Follow Us: <\/b>https:\/\/www.linkedin.com\/company\/statifacts<\/b><\/a><\/p>\n

Our Trusted Data Partners:<\/b><\/p>\n

Precedence Research<\/b><\/a> | <\/b>Towards Healthcare<\/b><\/a> | <\/b>Nova One Advisor<\/b><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"According to Statifacts, the global antibody discovery market size is projected to surpass USD 20.43 billion by 2034,…\n","protected":false},"author":3,"featured_media":70031,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[64,135,67,132,68],"class_list":{"0":"post-70030","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-markets","8":"tag-business","9":"tag-markets","10":"tag-united-states","11":"tag-unitedstates","12":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/114868904460009072","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/70030","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=70030"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/70030\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/70031"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=70030"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=70030"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=70030"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}